Drug Target Review

DECEMBER 20, 2024

Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drug development has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drug development.

Clinical Trials 128

Clinical Trials Trials Pharmaceuticals Drug Development 128

Broad Institute

DECEMBER 18, 2023

Brain disorders are difficult to study and many drug candidates have failed in clinical trials, causing pharmaceutical companies to reduce their investments or even exit the field entirely.

Drug Development 130

Drug Development Clinical Trials Drugs Disease 130

DrugBank

OCTOBER 17, 2024

Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drug development lifecycle. This was seen in the case of the BRAF V600E mutation test for melanoma patients receiving vemurafenib.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Drug Patent Watch

DECEMBER 12, 2024

Identifying branded drugs with a low likelihood of generic entry has become a crucial strategy for companies looking to expand their product portfolio through in-licensing. This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies.

Licensing 92

Licensing Licensing Drugs Biosimilars 92

Drug Patent Watch

DECEMBER 9, 2024

This approach has led to the discovery of numerous potential drug candidates. From Lab to Market: The Long Road of Drug Development Once a promising compound is identified, it enters the long and costly process of drug development. Q: How long does a drug patent last?

Drugs 96

Drugs Drug Development Pharmaceuticals Production 96

Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

DS in Pharmatics

FEBRUARY 27, 2023

When pharmaceutical companies develop a new drug product for the market, there are many different steps a potential product must go through to determine and control its safety, manufacturability, effectiveness and reliability. CMC is done during […]

Drug Development 52

Drug Development Pharmaceutical Companies Drugs Pharmaceuticals 52

thought leadership

MARCH 18, 2025

Question & Answer with Sander Vinks, PhD, PharmD, FCP, Regarding MIDD and M&S Unlocking the Power of Model-Informed Drug Development (MIDD) and Modeling & Simulation (M&S) In the ever-evolving landscape of drug development, efficiency, precision, and regulatory success are paramount.

Drug Development 40

Drug Development Clinical Trials Pharmaceutical Companies FDA 40

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Pharmaceutical Companies Clinical Development Drug Development 98

Drug Patent Watch

DECEMBER 12, 2024

The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to outsource various stages of drug development and manufacturing. With the increasing complexity of drug development and the need for efficient, cost-effective solutions, selecting the right CDMO is crucial.

Drug Development 97

Drug Development Production Clinical Trials Pharmaceutical Companies 97

Conversations in Drug Development Trends

DECEMBER 7, 2023

At Worldwide, we understand that every program is different, which means every drug development path forward will be unique. Rather than settling for an “off-the-shelf” approach, you deserve a team that actively seeks customized solutions tailored to your specific study.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

DrugBank

MARCH 7, 2024

The Quest for Ozempic-Like Alternatives Ozempic, a GLP-1 receptor agonist developed by Novo Nordisk, has demonstrated remarkable efficacy in promoting weight loss and improving metabolic health. Key Players and Challenges For pharmaceutical giants like Novo Nordisk and Eli Lilly, 2024 presents both opportunities and challenges.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Clinical Trials Therapies 98

DrugBank

OCTOBER 4, 2024

Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities.

Pharmaceuticals 98

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 98

ACTO

DECEMBER 17, 2024

Yet, the critical question remains: How can pharmaceutical companies ensure responsible and compliant AI implementation while maximizing its potential for field teams? Such cross-functional collaboration ensures consistent implementation from drug development through commercialization.

Government 52

Government Compliance Pharmaceutical Companies Pharmaceuticals 52

Drug Target Review

DECEMBER 11, 2024

This issue poses a significant hurdle for drug developers, with no universal protocol currently in place to address these complexities. For small- and medium-sized pharmaceutical companies, outsourcing represents a strategic leap forward, offering a gateway to unparalleled expertise and cutting-edge analytical technologies.

International 52

International Laboratories Drugs Pharmacokinetics 52

Drug Patent Watch

AUGUST 26, 2024

The pharmaceutical industry has increasingly relied on Contract Development and Manufacturing Organizations (CDMOs) to support the development and commercialization of drugs. CDMOs offer a range of services, from drug development to manufacturing, allowing pharmaceutical companies to focus on their core competencies.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceuticals Drug Development Drugs 59

Alta Sciences

MARCH 27, 2024

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. a commercial stage pharmaceutical company.

Science 145

Science Disease FDA Approval Clinical Trials 145

Drug Target Review

MARCH 4, 2025

The MyPhenome test has already gained traction among obesity specialists, particularly in Chicago and Florida, and Phenomix has formed strategic partnerships with multiple pharmaceutical companies to support clinical trials and further analyse obesity-related data.

Therapies 52

Therapies Treatment Clinical Trials Science 52

Conversations in Drug Development Trends

APRIL 4, 2024

The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies. Understanding and implementing the ICH M10 guidelines is not just a regulatory requirement; it’s a step towards more efficient and effective pharmaceutical research.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

Drug Target Review

SEPTEMBER 19, 2023

In addition, these models at the current state are better for short term tests, over a week or two and cannot be used for acquiring data from long term drug exposures. Miniature organs as test beds for new drugs Organoids are miniature human organs with clusters of cells derived from stem cells and mimic specific tissues.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

DrugBank

APRIL 12, 2024

Over the past decade, the drug discovery landscape has been revolutionized by the adoption of artificial intelligence (AI) and machine learning (ML), witnessing early adopters leapfrog into pioneering technologies aimed at streamlining the drug development process and curtailing associated costs.

Drugs 98

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 98

DS in Pharmatics

FEBRUARY 24, 2023

Drug development is an immensely complex undertaking consisting of many different, interconnected processes. Specialist regulatory affairs consultants offer services to companies operating across this challenging industry.

Pharmaceutical Companies 52

Pharmaceutical Companies Regulations Drug Development Pharmaceuticals 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. Let’s dive in to uncover the role of digital health and data in driving faster drug development through improved diversity.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

DrugBank

JUNE 27, 2024

Additionally, integrating diverse data types is a high demand task , and obtaining generic active ingredients can be challenging, especially if the drug is no longer commercially available. Combinations of drugs that work alongside one another can enhance drug efficacy and reduce required doses , increasing the success rate of repurposing.

Drugs 98

Drugs Pharma Companies Clinical Trials Computational Chemistry 98

DrugBank

JANUARY 15, 2025

Characterized by small patient populations, high development costs, and complex regulatory pathways, these therapies navigate a landscape distinct from blockbuster drugs targeting common diseases.   The Orphan Drug Paradox Orphan drug development is often described as a "high-risk, high-reward" endeavor.

Drugs 52

Drugs Drug Development Clinical Trials Therapies 52

Crown Bioscience

MAY 4, 2021

Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

Altus Drug Development

JUNE 30, 2022

While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. This novel approach promises to create great advantages for the pharmaceutical companies who adopt it and might become the future of medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

H1 Blog

SEPTEMBER 14, 2023

As pharmaceutical companies turn to CROs (Clinical Research Organizations) for trial design and technology, there are new opportunities emerging with healthcare data intelligence that can help ensure a bright future for the industry and to make trials more effective, efficient and accessible. million data points.”

Clinical Trials 59

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 59

H1 Blog

JULY 30, 2024

This sets the stage for binding and enforceable components per Section 3601 of the Food and Drug Omnibus Reform Act (FDORA), which will come into effect 180 days after the final guidance is published. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

PPD

JULY 20, 2023

Key competencies for biotech and biopharma organizations to meet the new USP requirements for plastic packaging and manufacturing materials With the implementation date drawing nearer, drug developers should test their packaging systems to ensure they are compliant and adhere to patient safety goals, or quickly identify and qualify alternatives.

Packaging 52

Packaging Laboratories Pharmaceutical Companies Compliance 52

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As someone who describes himself as an “enthusiastic sceptic,” Wilkie is cautious but hopeful about the potential of AI in drug development. “I

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

thought leadership

JUNE 19, 2023

Across biotech startups and global pharmaceutical companies alike, Veeva Vault continues to expand market share. With 1,300+ customers, Veeva Systems is one of the largest providers of cloud solutions for the life sciences industry.

Pharmaceutical Companies 40

Pharmaceutical Companies Drug Development Science Pharmaceuticals 40

FDA Law Blog: Drug Discovery

MARCH 6, 2024

Charles assists clients across a range of FDA-related regulatory matters by providing timely strategic advice on new drug and biologic development and helping them tackle complex regulatory issues.

FDA 59

FDA Compliance Pharmaceuticals Pharmaceutical Companies 59

Altus Drug Development

JUNE 28, 2022

Ensuring access to safe and effective treatments is the main challenge faced by pharmaceutical companies big and small. Value-added medicines offer an efficient method to meet the needs of patients while stimulating innovation in the pharmaceutical industry. appeared first on Altus Drug Development.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Doctors Treatment 52